Compare XLO & PDSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XLO | PDSB |
|---|---|---|
| Founded | 2016 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.8M | 49.5M |
| IPO Year | 2021 | N/A |
| Metric | XLO | PDSB |
|---|---|---|
| Price | $0.65 | $0.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $2.00 | ★ $9.00 |
| AVG Volume (30 Days) | 527.5K | ★ 583.3K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $31,804,000.00 | N/A |
| Revenue This Year | $626.78 | N/A |
| Revenue Next Year | $79.08 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 588.40 | N/A |
| 52 Week Low | $0.62 | $0.70 |
| 52 Week High | $1.70 | $2.20 |
| Indicator | XLO | PDSB |
|---|---|---|
| Relative Strength Index (RSI) | 35.65 | 44.55 |
| Support Level | $0.65 | $0.76 |
| Resistance Level | $0.68 | $0.93 |
| Average True Range (ATR) | 0.03 | 0.06 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 17.98 | 22.29 |
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.